| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Deacetylasperulosidic acid does not have a single defined pharmacological target but exhibits multiple biological activities. It has antioxidant activity by increasing superoxide dismutase activity. The compound may act as a vitamin D receptor agonist. Its diverse biological effects suggest interactions with multiple cellular pathways involved in oxidative stress, inflammation, and cell proliferation.
|
|---|---|
| ln Vitro |
Deacetylasperulosidic acid scavenges free radicals, suppresses pro-inflammatory mediators, and protects tissues from oxidative damage. It has antioxidant activity by increasing superoxide dismutase activity. The compound has antigenic activity and inhibits the induction of chromosomal aberrations in hamster ovary cells. In vitro studies demonstrate its potential for antioxidant and anti-inflammatory applications.
|
| ln Vivo |
Deacetylasperulosidic acid decreases serum malondialdehyde levels and increases superoxide dismutase activity in rats at 50 mg/kg per day for seven days. It has hepatoprotective effects and inhibits chromosomal aberrations in mice. In vivo studies support its potential as an antioxidant and hepatoprotective agent. The compound can be used to prepare vitamin D receptor agonists and compositions for preventing atherosclerosis.
|
| Enzyme Assay |
In vitro enzyme assays for Deacetylasperulosidic acid may involve measuring superoxide dismutase (SOD) activity or assessing lipid peroxidation by measuring malondialdehyde (MDA) levels. The compound's antioxidant activity can be evaluated using DPPH, ABTS, or other free radical scavenging assays. Binding assays for vitamin D receptor could also be performed.
|
| Cell Assay |
Cellular assays for Deacetylasperulosidic acid are performed using various cell lines to assess its biological activities. Antioxidant activity is evaluated by measuring intracellular ROS levels using fluorescent probes. Anti-inflammatory activity is assessed by measuring pro-inflammatory cytokine production (e.g., TNF-α, IL-6) in stimulated cells. Anticancer activity is evaluated by assessing cell proliferation, apoptosis, and cell cycle progression in cancer cell lines. Chromosomal aberration assays are performed in hamster ovary cells.
|
| Animal Protocol |
In vivo animal studies for Deacetylasperulosidic acid are performed in rats. Animals are administered Deacetylasperulosidic acid at 50 mg/kg per day for seven days. Serum malondialdehyde levels and superoxide dismutase activity are measured to assess antioxidant effects. Hepatoprotective effects are evaluated in models of liver injury. Chromosomal aberration studies are performed in mice. The compound can be used to study prevention of atherosclerosis.
|
| ADME/Pharmacokinetics |
Deacetylasperulosidic acid has a molecular weight of 390.34 and molecular formula C16H22O11. It is soluble in DMF (5 mg/ml), DMSO (10 mg/ml), and PBS pH 7.2 (5 mg/ml). The compound has a UV absorbance maximum at 235 nm. It should be stored at -20°C and shipped at room temperature. Purity is typically ≥98%.
|
| Toxicity/Toxicokinetics |
Deacetylasperulosidic acid is generally considered to have low toxicity based on its use in animal studies at 50 mg/kg per day. The compound has antioxidant and hepatoprotective properties that may provide protection against oxidative damage. Standard laboratory safety precautions should be followed when handling the compound. No specific acute toxicity data have been reported in the literature.
|
| References | |
| Additional Infomation |
According to reports, gardenias, madder, and other organisms with available data contain deacetylated lasperosides.
Deacetylasperulosidic acid is a monoterpene glycoside originally isolated from D. macropodum. It has antioxidant, anti-inflammatory, hepatoprotective, and anticancer properties. The compound is known to scavenge free radicals, suppress pro-inflammatory mediators, and protect tissues from oxidative damage. Deacetylasperulosidic acid is an active ingredient of Hedyotis diffusa and can be used to prepare vitamin D receptor agonists and compositions for preventing atherosclerosis. The compound is for research use only and has not been approved for clinical use. It is also known as 10-Deacetylasperulosidic Acid. |
| Molecular Formula |
C16H22O11
|
|---|---|
| Molecular Weight |
390.34
|
| Exact Mass |
390.116
|
| CAS # |
14259-55-3
|
| PubChem CID |
12315350
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
744.1±60.0 °C at 760 mmHg
|
| Flash Point |
271.7±26.4 °C
|
| Vapour Pressure |
0.0±5.6 mmHg at 25°C
|
| Index of Refraction |
1.683
|
| LogP |
-2.48
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
632
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C1=C([C@@H]2[C@H]([C@H]1O)C(=CO[C@H]2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(=O)O)CO
|
| InChi Key |
ZVXWFPTVHBWJOU-YYFGDFGFSA-N
|
| InChi Code |
InChI=1S/C16H22O11/c17-2-5-1-7(19)10-6(14(23)24)4-25-15(9(5)10)27-16-13(22)12(21)11(20)8(3-18)26-16/h1,4,7-13,15-22H,2-3H2,(H,23,24)/t7-,8+,9+,10-,11+,12-,13+,15-,16-/m0/s1
|
| Chemical Name |
(1S,4aS,5S,7aS)-5-hydroxy-7-(hydroxymethyl)-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylic acid
|
| Synonyms |
Deacetylasperulosidic Acid; DAA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~256.19 mM)
H2O : ~50 mg/mL (~128.09 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5619 mL | 12.8093 mL | 25.6187 mL | |
| 5 mM | 0.5124 mL | 2.5619 mL | 5.1237 mL | |
| 10 mM | 0.2562 mL | 1.2809 mL | 2.5619 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
